Physician profile
Ralph Herbig
NPI 1700972429
$5,978.86
in general payments reported to CMS, 2019-2025
45 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $298 · 2021: $1,049 · 2022: $810 · 2023: $835 · 2024: $977 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,090.88 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,288.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $821.14 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $556.35 | 2021-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $442.86 | 2019-2025 | |
| Glaxosmithkline, LLC. | $316.80 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $239.59 | 2019-2025 | Takhzyro |
| Abbott Laboratories | $197.30 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.73 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $169.68 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $145.95 | 2024-2025 | Caplyta |
| Zyla Life Sciences, INC. | $135.63 | 2019-2020 | |
| Organogenesis INC. | $121.64 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $118.16 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $96.22 | 2019-2025 | Veozah, Myrbetriq |
| Actelion Pharmaceuticals US, INC. | $84.56 | 2025 | Uptravi, Opsumit |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Herbig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.